USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
25 Jul 2024 | 03:00 PM GMT

Masterclass: Approaches to Successful Reimbursement for DTx Commercialization

Anchored by:

Mike Rosenbluth
CEO
SWING THERAPEUTICS

Participants:

Mike Rosenbluth CEOSwing Therapeutics
Mike Rosenbluth
CEOSwing Therapeutics
Tessy Huss Director of Strategy , HLTH CommunityHLTH Community
Tessy Huss
Director of Strategy , HLTH CommunityHLTH Community
Aleksandar Penev Director of OperationsDaye
Aleksandar Penev
Director of OperationsDaye
Anna-Maria Heidinger Head of Digital Innovation HubDaiichi Sankyo Europe
Anna-Maria Heidinger
Head of Digital Innovation HubDaiichi Sankyo Europe
Chris Cera CEOArcweb Technologies
Chris Cera
CEOArcweb Technologies
Franziska Eckardt Senior Product LeadKoa Health
Franziska Eckardt
Senior Product LeadKoa Health
Jacob Jesson AdvisorJesson Partners
Jacob Jesson
AdvisorJesson Partners
Jerry Young Solution LeadNotable
Jerry Young
Solution LeadNotable
Joao Soares VP TechHLTH
Joao Soares
VP TechHLTH
Julie Fishman EIRYale Ventures
Julie Fishman
EIRYale Ventures
Leonardo Angelone Deputy DirectorThe National Institutes on Drug Abuse
Leonardo Angelone
Deputy DirectorThe National Institutes on Drug Abuse
Luke Pawley Customer Success ManagerHLTH Community
Luke Pawley
Customer Success ManagerHLTH Community
Malika bouazzaoui Head of Clinical Validationieso
Malika bouazzaoui
Head of Clinical Validationieso
Marina Araujo Director Performance Management PSPNovartis
Marina Araujo
Director Performance Management PSPNovartis
Richard Bunney DirectorDeviceology
Richard Bunney
DirectorDeviceology
Taiba Quraishi Innovation AssociateAlexion Pharmaceuticals
Taiba Quraishi
Innovation AssociateAlexion Pharmaceuticals

About this Meeting

The absence of clear reimbursement pathways for digital therapeutics (DTx) represents a critical barrier to their integration into mainstream healthcare, despite their potential to revolutionize treatment paradigms across a spectrum of conditions. This limitation not only stifles innovation but also restricts patient access to potentially life-changing interventions. 

As the healthcare landscape increasingly shifts towards digital solutions, it's imperative to address the commercialization challenges faced by DTx companies. The sustainability of DTx innovations hinges on the industry's ability to navigate these hurdles, making the exploration of viable commercialization strategies in the absence of traditional reimbursement mechanisms a topic of paramount importance.

Join this meeting to deep dive into critical questions:
  • How do the current reimbursement challenges specifically impact DTx companies and their stakeholders, including patients, healthcare providers, and payers?
  • What innovative business models can DTx companies employ to make their products accessible while ensuring business sustainability?
  • What does the future hold for DTx reimbursement, and what steps can the industry take to influence a shift towards more supportive policies and frameworks?